These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15077913)

  • 1. Somatostatin receptors: from basic science to clinical approach. Unlabeled somatostatin analogues-1: Prostate cancer.
    Mosca A; Dogliotti L; Berruti A; Lamberts SW; Hofland LJ
    Dig Liver Dis; 2004 Feb; 36 Suppl 1():S60-7. PubMed ID: 15077913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
    Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
    J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
    Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
    Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate.
    Bonkhoff H; Stein U; Remberger K
    Virchows Arch A Pathol Anat Histopathol; 1993; 423(4):291-4. PubMed ID: 7694424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine cells in tumour growth of the prostate.
    Abrahamsson PA
    Endocr Relat Cancer; 1999 Dec; 6(4):503-19. PubMed ID: 10730904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine differentiation and hormone-refractory prostate cancer.
    Abrahamsson PA
    Prostate Suppl; 1996; 6():3-8. PubMed ID: 8630226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do neuroendocrine cells in human prostate cancer express androgen receptor?
    Krijnen JL; Janssen PJ; Ruizeveld de Winter JA; van Krimpen H; Schröder FH; van der Kwast TH
    Histochemistry; 1993 Nov; 100(5):393-8. PubMed ID: 8307781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma.
    Berruti A; Dogliotti L; Mosca A; Gorzegno G; Bollito E; Mari M; Tarabuzzi R; Poggio M; Torta M; Fontana D; Angeli A
    Ann Oncol; 2001; 12 Suppl 2():S153-7. PubMed ID: 11762344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Prostate; 2002 Mar; 50(4):203-15. PubMed ID: 11870798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin.
    Xing N; Qian J; Bostwick D; Bergstralh E; Young CY
    Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroendocrine pathogenesis in adenocarcinoma of the prostate.
    Hansson J; Abrahamsson PA
    Ann Oncol; 2001; 12 Suppl 2():S145-52. PubMed ID: 11762343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence.
    Ito T; Yamamoto S; Ohno Y; Namiki K; Aizawa T; Akiyama A; Tachibana M
    Oncol Rep; 2001; 8(6):1221-4. PubMed ID: 11605036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
    Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A
    Prostate; 2001 May; 47(3):205-11. PubMed ID: 11351350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype].
    Bonkhoff H; Fixemer T
    Urologe A; 2004 Jul; 43(7):836-42. PubMed ID: 15048555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
    Alberti C
    G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies.
    Casella R; Bubendorf L; Sauter G; Moch H; Mihatsch MJ; Gasser TC
    J Urol; 1998 Aug; 160(2):406-10. PubMed ID: 9679888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of chromogranins and regulation of their synthesis and processing in a neuroendocrine prostate tumor cell line.
    Ischia R; Culig Z; Eder U; Bartsch G; Winkler H; Fischer-Colbrie R; Klocker H
    Prostate Suppl; 1998; 8():80-7. PubMed ID: 9690667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
    Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
    Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine differentiation in prostatic carcinoma.
    Abrahamsson PA
    Prostate; 1999 May; 39(2):135-48. PubMed ID: 10221570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.